Schedule 13G ownership disclosure

Karyopharm Therapeutics Inc

COMMON STOCK · CUSIP: 48576U205

Event date: 2025-06-30

Filing-level shares
728,766
Percent of class
8.4%
  • T. Rowe Price Investment Management, Inc.

    Shares: 728,766 · Class: 8.4%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001897612-25-000365
Form type
SCHEDULE 13G
Filer
Karyopharm Therapeutics Inc.
CIK
CIK 1503802
Filed
Aug 14, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub